Adidas Unveils Innovative Team Kits for Paris 2024 Olympics and Paralympics 
Why is toddler milk so popular? Follow the money 
Nissan Cuts Profit Forecasts Amidst Sales Slump and Natural Disaster 
Will global oil supply be at risk if Iran and Israel pull the Middle East into war? 
Industry shutdowns are messy and painful: 4 lessons Australia’s coal sector can learn from car-makers about bowing out 
Starbucks Revamps Cups to Ease Plastic Waste; New Design to Roll Out in US, Canada 
How India’s economy has fared under ten years of Narendra Modi 
Polestar to Launch Polestar 4 Pure EV in South Korea 
TSMC to Hike Prices for Chips Made Outside Taiwan, Impacting Global Device Costs 
Huawei Unveils Pura 70 Series to Rival Apple's Dominance in China's Smartphone Arena 
Tesla Cybertruck Recall: NHTSA Flags 3,878 Units for Pedal Issue 
The idea that US interest rates will stay higher for longer is probably wrong 
Be wary of the ‘vibes’: positive investor sentiment doesn’t necessarily match the true value of stocks 
South Korean pharmaceutical and biotech companies are collaborating to develop new drugs using artificial intelligence (AI).
AI can predict whether a chemical compound is suitable for human use, thereby speeding up the identification of potential substances and enabling the selection of appropriate clinical patients.
There are over 100 cases where candidate substances for new drugs are under development using AI, with over 50 percent carried out through collaborations between domestic and foreign companies, according to the Korea Pharmaceutical and Bio-pharma Manufacturers Association.
HK inno.N Corp. and AinB recently signed an MOU to identify a new antibody candidate substance for cell and gene therapies and establish an antigen design platform for vaccine development.
Last year, Pharos iBio inked a deal with Yuhan Corp. to promote the joint study and technology transfer of the AI-based KRAS inhibitor.
This company is now carrying out a phase 1 clinical trial in Korea and Australia after developing PHI-101, a candidate substance for the treatment of leukemia, using its AI platform, Chemiverse.
Moreover, Oncocross, which has AI technology to identify the optimal disease for drugs, signed a joint study and development contract with Boryung Corp. in February to expand the indications of hypertension treatment.
